ReviewVirology2011
Novel approaches in anti-arenaviral drug development.
Review in Virology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Understanding Viral Haemorrhagic Fevers: Virus Diversity, Vector Ecology, and Public Health Strategies.Pathogens (Basel, Switzerland) · 2024Review
- Entry inhibitors as arenavirus antivirals.Frontiers in microbiology · 2024Review
- Pseudotyped Viruses for Mammarenavirus.Advances in experimental medicine and biology · 2023Article
- SAR studies of 4-acyl-1,6-dialkylpiperazin-2-one arenavirus cell entry inhibitors.Bioorganic & medicinal chemistry letters · 2019Article
- The ReFRAME library as a comprehensive drug repurposing library to identify mammarenavirus inhibitors.Antiviral research · 2019Article
- Crystal structures ofIUCrJ · 2018Article
- An Overview of Hepatitis B Virus Surface Antigen Secretion Inhibitors.Frontiers in microbiology · 2018Review
- Lassa Virus Cell Entry via Dystroglycan Involves an Unusual Pathway of Macropinocytosis.Journal of virology · 2016Article
- Selective inhibitor of endosomal trafficking pathways exploited by multiple toxins and viruses.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Highlights in antiviral drug research: antivirals at the horizon.Medicinal research reviews · 2013Review
- Isolation, identification, and characterization of novel arenaviruses, the etiological agents of boid inclusion body disease.Journal of virology · 2013Article
- Review
- Molecular mechanism of arenavirus assembly and budding.Viruses · 2012Review
- Review
- Drug discovery technologies and strategies for Machupo virus and other New World arenaviruses.Expert opinion on drug discovery · 2012Review
- Viral hemorrhagic fevers: advancing the level of treatment.BMC medicine · 2012Review
- Severe hemorrhagic fever in strain 13/N guinea pigs infected with Lujo virus.PLoS neglected tropical diseases · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Hemorrhagic fevers caused by arenaviruses are among the most devastating emerging human diseases. Considering the number of individuals affected, the current lack of a licensed vaccine, and the limited therapeutic options, arenaviruses are arguably among the most neglected tropical pathogens and the development of efficacious anti-arenaviral drugs is of high priority. Over the past years significant efforts have been undertaken to identify novel potent inhibitors of arenavirus infection. High throughput screening of small molecule libraries employing pseudotype platforms led to the discovery of several potent and broadly active inhibitors of arenavirus cell entry that are effective against the major hemorrhagic arenaviruses. Mechanistic studies revealed that these novel entry inhibitors block arenavirus membrane fusion and provided novel insights into the unusual mechanism of this process. The success of these approaches highlights the power of small molecule screens in antiviral drug discovery and establishes arenavirus membrane fusion as a robust drug target. These broad screenings have been complemented by strategies targeting cellular factors involved in productive arenavirus infection. Approaches targeting the cellular protease implicated in maturation of the fusion-active viral envelope glycoprotein identified the proteolytic processing of the arenavirus glycoprotein precursor as a novel and promising target for anti-arenaviral strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.